<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03365687</url>
  </required_header>
  <id_info>
    <org_study_id>MP-21-2018-1657</org_study_id>
    <nct_id>NCT03365687</nct_id>
  </id_info>
  <brief_title>Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers</brief_title>
  <acronym>DIVA</acronym>
  <official_title>Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers: a Randomized Controlled Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EURO-PHARM International Canada inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this 7-month randomized controlled trial, children aged 1 to less than 6 years, with
      recurrent asthma attacks triggered mostly by colds, will receive a high dose of vitamin D or
      a placebo every 3.5 months during their usual clinic visit, and a daily supplement of vitamin
      D or a placebo. This study will test whether children in vitamin D group have less frequent
      and less severe asthma exacerbations compared with those receiving placebo.The study will
      also document the safety profile of this strategy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter triple-blind randomized parallel-group, placebo-controlled trial of
      vitamin D3 supplementation. Children aged 1-5 (&lt;6) years with physician-diagnosed asthma
      predominantly triggered by upper respiratory tract infection will be screened for enrolment
      in paediatric asthma, respiratory or allergy clinics and the ED departments and randomized
      between Sept 1 to November 30, annually (4 recruitment years).

      Using a computer-generated random list, stratified by site, children will be allocated (1:1)
      using permuted block randomisation method to enhance concealment.

      Children will be followed for 7 months, with 3 visits every 3.5 months with repeated urine
      (for calcium:creatinine ratio) and blood samples. In addition, ten (10) days after each
      bolus, urine will be sampled for urinary calcium:creatinine ratio. In case of elevated urine
      calcium:creatinine ratio, a blood sample may be needed primarily for markers of calcium
      metabolism and exploratory outcomes. Only patients enrolled at CHU Sainte-Justine and
      Montreal Children's Hospital will receive a systematic home visit 10 days after first bolus
      for both urine and blood samples. There will be 7 follow-up phone calls, at week 1 and then
      monthly, to inquire about exacerbations and URTIs, remind parents to complete questionnaires
      and to collect a nasal swab at each exacerbation and screen for adverse events.

      The main outcome is the number of courses of rescue oral corticosteroids (OCS) per child
      during the study period. Several secondary outcomes will be documented using biological
      samples and validated questionnaires to ascertain laboratory-confirmed respiratory
      infections, intensity and severity of exacerbations, de-intensification of preventive asthma
      therapy, cost effectiveness, and safety profile. A sample of 432 per arm (400+7.5% attrition)
      per arm will provide 80% power with a two-tailed alpha of 5% to detect a 25% relative
      reduction in the number of exacerbations requiring OCS per child.

      An intention-to-treat (ITT) analysis will be carried out with all randomised children.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomised, quadruble-blind, placebo-controlled, parallel-group multicentre trial of vitamin D3 supplementation.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The manufacturer, Europharm, will provide the active vitamin D3 and placebo preparations, identical in appearance and taste, in coded latex-free bottles. A web-based randomisation system will allow Site pharmacies to login, obtain allocated treatment, prepare the 2 mL bolus in coded syringes and the coded bottles containing the daily dose, and dispense study drugs in masked kits.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of asthma exacerbations per child treated with rescue oral corticosteroids</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the mean number of exacerbations treated with rescue oral corticosteroids/child</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory-confirmed respiratory infections</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in mean number of laboratory-confirmed respiratory infections during asthma exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of asthma symptoms during asthma exacerbations</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the mean severity of asthma symptoms documented on the 'Asthma Flare-up Diary for Young Children'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of asthma symptoms during asthma exacerbations</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the mean duration of asthma symptoms documented on the validated 'Asthma Flare-up Diary for Young Children'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of use of rescue β2-agonists during asthma exacerbations</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the mean cumulative use of rescue β2-agonists during exacerbations documented on the validated 'Asthma Flare-up Diary for Young Children'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parents' functional status during asthma exacerbations</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the mean parents' functional status during exacerbation as documented on the validated 'Effect of a child's asthma flare-up on parents questionnaire'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of ED visits for asthma exacerbations</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in number of ED visits for asthma exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>De-intensification of preventive asthma therapy</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in proportion of children with de-intensification of preventive asthma therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention cost-effectiveness</measure>
    <time_frame>7 months</time_frame>
    <description>Cost of intervention vs. cost (family expenses and health care) of exacerbations</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hypercalciuria</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the proportion of children with ≥1 occurrence of hypercalciuria (urinary calcium: creatinine greater than 1.25 mmol/mmol for children aged 1-2 yrs, or greater than 1 mmol/mmol for those aged 2-5 yrs)</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypercalcemia</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the proportion of children with ≥1 occurrence of hypercalcemia</description>
  </other_outcome>
  <other_outcome>
    <measure>Elevated serum 25-hydroxyvitamin D</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the proportion of children with ≥1 occurrence of elevated serum 25OHD (greater than 250 nmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Health Events</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the distribution of adverse health events</description>
  </other_outcome>
  <other_outcome>
    <measure>Gene expression</measure>
    <time_frame>3.5 months</time_frame>
    <description>Group difference in the change in gene expression between baseline and 3.5 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum and nasal metabolome</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the change in serum and nasal metabolome over 7 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Distribution of laboratory-confirmed respiratory infections</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the distribution of laboratory-confirmed respiratory infections</description>
  </other_outcome>
  <other_outcome>
    <measure>Lung function</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the change from baseline in lung function measured by respiratory resistance or lung clearance index at 7 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Bone remodelling</measure>
    <time_frame>3.5 months</time_frame>
    <description>Group difference in the change in markers of bone remodelling</description>
  </other_outcome>
  <other_outcome>
    <measure>Severity of respiratory infection</measure>
    <time_frame>7 months</time_frame>
    <description>Group difference in the severity of respiratory infection ascertained on the adapted 'Respiratory Symptoms Questionnaire'</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">865</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D supplement (100,000 IU) orally at baseline and at 3.5 months with daily 400 IU vitamin D for 7 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally at baseline and at 3.5 months with daily placebo during 7 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 1-5 years

          -  Physician-diagnosed asthma (as per the 2015 Canadian Position Paper on the diagnosis
             of preschool asthma)

          -  ≥1 asthma exacerbation requiring rescue oral corticosteroids (OCS) in the past 6
             months or ≥2 in the past 12 months (pharmacy/medical records)

          -  ≥4 URTIs in the past 12 months (parental report)

          -  URTIs as the main asthma trigger (parental report)

        Exclusion Criteria:

          -  Intake or intention to use &gt; 400 IU/day of vitamin D3 supplements

          -  Extreme prematurity (&lt; 28 week gestation)

          -  No vitamin D supplementation when breast-fed

          -  Vitamin D restrictive diets, that is, minimal milk intake

          -  Recent immigrants from regions at high risk of rickets

          -  Recent refugees

          -  Undernourished children

          -  Other chronic respiratory disease

          -  Condition(s) or drug(s) that alter calcium or vitamin D absorption or metabolism

          -  Anticipated difficulty with follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francine M Ducharme, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francine M Ducharme, MD</last_name>
    <phone>514-345-4931</phone>
    <phone_ext>4398</phone_ext>
    <email>francine.m.ducharme@umontreal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ilona Shemyakina, BSc</last_name>
    <phone>514-345-4931 Ext. 7243</phone>
    <phone_ext>4053</phone_ext>
    <email>ilona.shemyakina@umontreal.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Noseworthy, MD</last_name>
      <email>mary.noseworthy@ahs.ca</email>
    </contact>
    <investigator>
      <last_name>Mary Noseworthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Piushkumar Mandhane, MD</last_name>
      <email>mandhane@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Piushkumar Mandhane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Connie Yang, MD</last_name>
      <phone>1-6048752000</phone>
      <phone_ext>4931</phone_ext>
      <email>connie.yang@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Connie Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 2V5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Bock, MD</last_name>
      <phone>1-5196858824</phone>
      <email>Dirk.Bock@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Dirk Bock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dhenuka Radhakrishnan, MD</last_name>
      <phone>1-6137377600</phone>
      <phone_ext>2868</phone_ext>
      <email>dradhakrishnan@cheo.on.ca</email>
    </contact>
    <investigator>
      <last_name>Dhenuka Radhakrishnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Padmaja Subbarao, MD</last_name>
      <email>padmaja.subbarao@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Padmaja Subbarao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital (MCH)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Duncan Lejtenyi, MSc</last_name>
      <phone>1-5144124400</phone>
      <phone_ext>22369</phone_ext>
      <email>duncan.lejtenyi@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Reza Alizadehfar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Québec-Université Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Daigneault, MD</last_name>
      <email>patrick.daigneault@mail.chuq.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Patrick Daigneault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chantal Lemire, MD</last_name>
      <email>Chantal.Lemire@USherbrooke.ca</email>
    </contact>
    <investigator>
      <last_name>Chantal Lemire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2017</study_first_submitted>
  <study_first_submitted_qc>December 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Professor Francine Ducharme</investigator_full_name>
    <investigator_title>Pediatrician</investigator_title>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Respiratory viral infection</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Asthma exacerbations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

